<DOC>
	<DOC>NCT02100527</DOC>
	<brief_summary>This is a 6 week study to characterize the safety, tolerability and effects of PF-05175157 administered for 6 weeks in subjects with moderate to severe acne vulgaris.</brief_summary>
	<brief_title>Study Of Safety, Tolerability And Effects Of PF-05175157 In Adults With Moderate To Severe Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Males 18 years or older diagnosed with moderate to severe acne vulgaris who are otherwise healthy. Normal spirometry at screening (FEV1 and FVC (Forced Vital Capacity)at least 80% predicted). Minimum of 20 inflammatory lesions on the face. Willing to discontinue other acne treatments prior to and during the study period through followup. Subjects with active nodulocystic acne. Subjects unwilling to comply with lifestyle guidelines, commit to study visits, and perform study procedures. History of dry eye or other known disease that affects the sclera or cornea. History of pulmonary disease or inability to adequately perform testing.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>oral dosing</keyword>
	<keyword>moderate to severe acne vulgaris</keyword>
</DOC>